CRN, AHPA say FDA should consider combo products
This article was originally published in The Tan Sheet
Executive Summary
FDA should allow supplement and drug combination products in the marketplace, executives from the Council for Responsible Nutrition and the American Herbal Products Association say at a Jan. 30 Food, Drug and Law Institute conference in Washington. "It's to FDA's advantage to help the industry" market combination products because they will benefit the public health, CRN President Steve Mister notes. Mister says FDA should advise all manufacturers on how to comply so they have "equal footing" in the marketplace. AHPA President Michael McGuffin says, "Don't tell us what we can't do. Tell us how we can do it, in a reasonable and responsible manner." FDA in October 2008 warned Bayer HealthCare that its two products combining aspirin with dietary supplement ingredients are unapproved new drugs (1"The Tan Sheet" Nov. 3, 2008, p. 9)